CJC-1295

Description

CJC-1295 Without DAC Mechanism Profile

CJC-1295 without DAC is investigated for its interaction with the growth hormone-releasing hormone receptor (GHRHR). GHRH receptor activation is associated with intracellular signaling pathways involved in the regulation of growth hormone secretion within experimental endocrine models.

The peptide acts as a GHRH-related receptor agonist and has been studied for its ability to stimulate signaling associated with pituitary somatotroph cells. These cells are involved in the physiological regulation of growth hormone release.

Because the non-DAC form lacks the albumin-binding Drug Affinity Complex used in longer-acting variants, researchers may study it when investigating comparatively shorter-duration peptide activity. These mechanisms describe areas of laboratory research and should not be interpreted as therapeutic or performance claims.

CJC-1295 Molecular Research Profile

CJC-1295 without DAC belongs to a class of synthetic peptides developed from growth hormone-releasing hormone-related sequences. Modifications to the peptide are designed to support experimental stability while preserving activity at the GHRH receptor.

GHRH is an endogenous hypothalamic peptide involved in signaling between the hypothalamus and anterior pituitary. Laboratory research involving GHRH analogues can help characterize receptor activation, intracellular signaling, and endocrine feedback mechanisms.

CJC-1295 without DAC is therefore of interest in experimental models focused on peptide-receptor pharmacology and the growth hormone axis.

Why CJC-1295 Without DAC Is Studied

CJC-1295 without DAC has attracted research interest because it provides a modified GHRH-related peptide for investigating growth hormone secretory pathways under controlled experimental conditions. Researchers may examine receptor activation, downstream signaling, pituitary cellular responses, and differences between shorter-acting and extended-duration GHRH-related compounds.

The non-DAC format is particularly relevant to comparative peptide research because it does not contain the Drug Affinity Complex used to prolong circulation through albumin binding in DAC-containing variants.

GHRH Receptor Research

The growth hormone-releasing hormone receptor is a G-protein-coupled receptor expressed prominently in pituitary somatotroph cells. Activation of this receptor initiates intracellular signaling associated with growth hormone secretory pathways.

Research involving CJC-1295 without DAC may investigate receptor binding, cyclic AMP-related signaling, and downstream cellular responses associated with GHRH receptor activation. Such studies contribute to the broader understanding of hypothalamic-pituitary signaling and peptide-mediated endocrine regulation.

Growth Hormone Axis Research

The growth hormone axis involves coordinated signaling between the hypothalamus, pituitary gland, and peripheral tissues. Endogenous GHRH participates in this system by signaling the pituitary to regulate growth hormone secretion.

Synthetic GHRH-related peptides such as CJC-1295 without DAC can be used in laboratory models to investigate components of this signaling network.

Research may focus on receptor pharmacology, endocrine feedback, cellular secretory responses, and molecular signaling associated with the growth hormone axis. These research areas do not establish clinical benefits for this research product.

Without DAC Research Significance

The term without DAC indicates that this CJC-1295 research peptide does not incorporate a Drug Affinity Complex intended to promote prolonged albumin binding.

This distinction is scientifically important because DAC-containing and non-DAC variants can exhibit different pharmacokinetic characteristics in experimental systems.

The non-DAC form can therefore be useful in comparative laboratory research examining peptide duration, receptor signaling patterns, and differences between modified GHRH-related compounds.

Endocrine Signaling Research

Endocrine signaling depends on coordinated interactions between peptide hormones, receptors, and downstream intracellular pathways.

CJC-1295 without DAC has been investigated as a research compound for studying GHRH-related signaling within experimental endocrine systems. Laboratory studies may evaluate receptor activation, signaling kinetics, and cellular responses under defined conditions.

These investigations contribute to the scientific characterization of synthetic peptide analogues and their interactions with endocrine receptor systems.

Laboratory Research Applications

CJC-1295 without DAC may be investigated in appropriately designed laboratory research involving peptide biology, receptor pharmacology, and endocrine signaling.

• GHRH receptor research: Investigation of interactions with the growth hormone-releasing hormone receptor.
• Cell signaling: Study of intracellular signaling following receptor activation.
• Endocrine research: Investigation of hypothalamic-pituitary signaling pathways.
• Growth hormone axis research: Experimental study of molecular pathways involved in growth hormone regulation.
• Comparative peptide research: Comparison between non-DAC and DAC-containing GHRH-related compounds.
• Peptide pharmacology: Characterization of receptor activity and signaling behavior in controlled experimental systems.

These represent scientific research categories and are not recommendations for clinical, veterinary, or personal use.

Vial Specifications